2016

The analysis compares the immune microenvironment of uveal melanoma and skin cutaneous melanoma FOSTER CITY, CALIFORNIA, UNITED STATES, July 21, 2016 /EINPresswire.com/ — MedGenome will be presenting its analysis comparing the immune microenvironment of uveal melanoma and skin cutaneous melanoma at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, September 25-28, 2016, New York. The remarkable […]

ZellNet will be a distributor for MedGenome’s OncoPept™ – a powerful end to end genomics platform to accelerate immune-oncology research. FOSTER CITY, CA, UNITED STATES, June 4, 2016 /EINPresswire.com/ — MedGenome announced a strategic partnership with ZellNet Consulting – a trusted provider of immune monitoring services for over 18 years. This arrangement seamlessly integrates MedGenome’s

FOSTER CITY, California, May 6, 2016 /PRNewswire/ — MedGenome will present its abstract titled ‘SAGVDB – An integrated resource for South Asian genome variation’ at the Big Data Bioinformatics Conference, to be held on May 26th-27th 2016 in Boston, MA. A deep understanding of human genetic variation is essential for investigating the relationship between genotype

OncoPeptTOPE™ is freely accessible online to DNA / Peptide vaccine researchers FOSTER CITY, CA, UNITED STATES, April 29, 2016 /EINPresswire.com/ — MedGenome recently announced that its proprietary OncoPeptTOPE™ database of neo-antigens and neo-epitopes derived from genetic alterations using TCGA data will be made freely accessible to researchers in the cancer immunotherapy space. The database captures

FOSTER CITY, CA, UNITED STATES, April 12, 2016 /EINPresswire.com/ — MedGenome will present results from its analysis of the whole genome sequence data from the Wellderly study (Scripps Translational Science Institute) at the Diabetes Summit 2016, from April 25-27th in Boston, MA. The study titled “Whole Genome Sequencing data from the Wellderley study identifies rare

The MedGenome proprietary platform, currently leveraged by various commercial and academic collaborators in the US, will be presented at AACR 2016. FOSTER CITY, CALIFORNIA, UNITED STATES, March 30, 2016 /EINPresswire.com/ — MedGenome will present an abstract on its proprietary data analysis and interpretation platform for Cancer discovery research at the AACR Annual Meeting 2016, organised

FOSTER CITY, California, March 14, 2016 /PRNewswire/ — MedGenome presented data on its proprietary cancer immunotherapy platform, OncoPept that predicts and prioritizes T-cell neo-epitopes in human and mouse cancers at the Molecular Medicine Tri- Conference 2016, which took place on March 6 – 11, 2016 at San Francisco, CA. Many pre-clinical and clinical studies have

FOSTER CITY, California, March 14, 2016 /PRNewswire/ — MedGenome presented data on its proprietary cancer immunotherapy platform, OncoPept that predicts and prioritizes T-cell neo-epitopes in human and mouse cancers at the Molecular Medicine Tri- Conference 2016, which took place on March 6 – 11, 2016 at San Francisco, CA. Many pre-clinical and clinical studies have

A comprehensive genomics study has used MedGenome’s OncoMD knowledge base to identify cancer relevant alterations in Mesothelioma, a deadly cancer. FOSTER CITY , California, March 1, 2016 /PRNewswire/ — Mesothelioma is a relatively rare cancer with a five year survival rate between five and ten percent. The global death due to Mesothelioma is estimated to be ~43,000 per year.

FOSTER CITY, California, February 24, 2016 /PRNewswire/ — MedGenome acquires the assets of Lifecode Health and its 13,000 sq ft lab in Foster City, CA to expland its genomic services to biotech and pharma companies in the US. MedGenome, the market leader for genomic diagnostics in South Asia and a leading provider of genomics research